Department of Medical Sciences and Uppsala Clinical Research Center, Uppsala University, Uppsala.
Department of Clinical Sciences, Danderyd Hospital, Karolinska Institutet, Stockholm, Sweden.
Am Heart J. 2018 Mar;197:70-76. doi: 10.1016/j.ahj.2017.11.012. Epub 2017 Dec 5.
Cardiac troponin (cTn) levels reflect infarct size and depressed left ventricular ejection fraction (LVEF) in patients with non-ST elevation acute coronary syndrome (NSTE-ACS). However, there is very limited information on whether cTn measured with a high-sensitivity (hs) assay would provide incremental prognostic information to the LVEF in NSTE-ACS patients.
This was a registry-based study (SWEDEHEART registry) investigating 20,652 NSTE-ACS patients with available information on hs-cTnT (highest level recorded during the hospitalization) and the LVEF estimated using echocardiography. All patients had been followed for 1 year.
Hs-cTnT levels independently predicted major cardiovascular events (MACE) in cohorts with normal, slightly depressed, moderately depressed, and severely depressed LVEF. The adjusted hazard ratios in these cohorts were 1.18 (95% CI 1.13-1.23), 1.12 (95% CI 1.06-1.18), 1.12 (95% CI 1.06-1.19), and 1.21 (95% CI 1.13-1.30), respectively. Hs-cTnT levels were particularly predictive for cardiovascular mortality and readmission for heart failure. Excluding patients with previous cardiac disease did not affect the overall interrelations of hs-cTnT and LVEF with MACE.
Hs-cTnT levels provide incremental prognostic value independent of the LVEF in patients with NSTE-ACS. Hs-cTnT is particularly predictive for MACE in patients with severely depressed LVEF but also in those with a normal LVEF. Accordingly, a normal LVEF should not be used as an argument not to target patients to thorough workup.
在非 ST 段抬高型急性冠脉综合征(NSTE-ACS)患者中,心肌肌钙蛋白(cTn)水平反映梗死面积和左心室射血分数(LVEF)降低。然而,关于高敏(hs)检测方法测量的 cTn 是否会为 NSTE-ACS 患者的 LVEF 提供额外的预后信息,相关信息非常有限。
这是一项基于注册的研究(SWEDEHEART 注册研究),纳入了 20652 例 NSTE-ACS 患者,这些患者均有 hs-cTnT(住院期间记录的最高值)和超声心动图估计的 LVEF 相关信息。所有患者均随访 1 年。
hs-cTnT 水平独立预测了 LVEF 正常、轻度降低、中度降低和重度降低的 NSTE-ACS 患者的主要心血管事件(MACE)。在这些队列中,调整后的风险比分别为 1.18(95%CI 1.13-1.23)、1.12(95%CI 1.06-1.18)、1.12(95%CI 1.06-1.19)和 1.21(95%CI 1.13-1.30)。hs-cTnT 水平对心血管死亡率和心力衰竭再入院的预测作用尤其明显。排除既往有心脏疾病的患者并不影响 hs-cTnT 和 LVEF 与 MACE 的总体相关性。
hs-cTnT 水平为 NSTE-ACS 患者提供了独立于 LVEF 的额外预后价值。hs-cTnT 对 LVEF 严重降低的患者和 LVEF 正常的患者的 MACE 预测作用尤其明显。因此,正常的 LVEF 不应作为不全面检查患者的理由。